AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21776573 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 60
Study 21776573 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 60
Study 21776573 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 60
Study 19159947 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamon supplementation (3 g day(‐1))
Number of subjects: 8
Study 17517346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing at 60 ppm
Number of subjects: 13
Study 17517346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing at 75 ppm
Number of subjects: 13
Study 17517346 — intervention group
Group type: COMPARATOR
Intervention: Pacing at 90 ppm
Number of subjects: 13
Study 15447908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified spread (FS)
Number of subjects: 374
Study 15447908 — intervention group
Group type: COMPARATOR
Intervention: Unfortified spread (US)
Number of subjects: 374
Study 15447908 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 374
Study 12151917 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium 20 mg
Number of subjects: 202
Study 12151917 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib sodium 40 mg
Number of subjects: 202
Study 12151917 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 202
Study 12151917 — intervention group
Group type: COMPARATOR
Intervention: Intravenous morphine 4 mg
Number of subjects: 202
Study 12151917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 10409961 — intervention group
Group type: EXPERIMENTAL
Intervention: Kit A (System 4)
Number of subjects: 57
Study 10409961 — intervention group
Group type: COMPARATOR
Intervention: Kit B (Charing Cross)
Number of subjects: 57
Study 10409961 — intervention group
Group type: COMPARATOR
Intervention: Kit C (Profore)
Number of subjects: 57
Study 7792125 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefpodoxime proxetil (8 mg/kg/day twice daily)
Number of subjects: 1188
Study 7792125 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid
Number of subjects: 1188
Study 7792125 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 1188
Study 7792125 — intervention group
Group type: COMPARATOR
Intervention: Cefixime
Number of subjects: 1188
Study 2284602 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer telephone network
Number of subjects: 0
Study 2284602 — intervention group
Group type: COMPARATOR
Intervention: Informational lecture series accessed over the telephone
Number of subjects: 0
Study 388085 — intervention group
Group type: EXPERIMENTAL
Intervention: Methicillin for 3 days
Number of subjects: 105
Study 388085 — intervention group
Group type: COMPARATOR
Intervention: Saline-placebo for 3 days
Number of subjects: 105
Study 388085 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin prophylaxis
Number of subjects: 105
Study 31255371 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling plus a low-cost, intradialytic, protein-rich meal (200 mL milk plus two egg whites) thrice weekly for 3 months.
Number of subjects: 0
Study 31255371 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counseling alone.
Number of subjects: 0
Study 31074184 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 250–500 mg daily plus bumetanide 1–2 mg bid
Number of subjects: 34
Study 31074184 — intervention group
Group type: COMPARATOR
Intervention: High-dose loop diuretics (bumetanide bid with daily dose twice the oral maintenance dose)
Number of subjects: 34
Study 28304210 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF + CMX
Number of subjects: 18
Study 28304210 — intervention group
Group type: COMPARATOR
Intervention: CAF
Number of subjects: 18
Study 26115762 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise group for AS
Number of subjects: 80
Study 26115762 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based exercise group for AS
Number of subjects: 80
Study 26115762 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise group for MS
Number of subjects: 80
Study 26115762 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based exercise group for MS
Number of subjects: 80
Study 23286595 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive telephone counseling with tailored self‐directed materials (including nicotine patches, if not contraindicated)
Number of subjects: 496
Study 23286595 — intervention group
Group type: COMPARATOR
Intervention: Tailored self‐directed materials (including nicotine patches, if not contraindicated)
Number of subjects: 496
Study 21585706 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab + cisplatin-based chemotherapy
Number of subjects: 1000
Study 21585706 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed + cisplatin
Number of subjects: 1000
Study 19050829 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg zinc daily for 4 weeks
Number of subjects: 16
Study 16962106 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulus-aided embryo transfer with cocultured embryos and expanded cumulus cells
Number of subjects: 517
Study 16962106 — intervention group
Group type: COMPARATOR
Intervention: Control group (coculture without cumulus-aided embryo transfer)
Number of subjects: 517
Study 15623197 — intervention group
Group type: EXPERIMENTAL
Intervention: Local symptoms of SVT (pain, erythema, swelling)
Number of subjects: 46
Study 15623197 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus size
Number of subjects: 46
Study 15623197 — intervention group
Group type: EXPERIMENTAL
Intervention: DVT diagnosis
Number of subjects: 46
Study 12166338 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron 0.3 mg
Number of subjects: 194
Study 12166338 — intervention group
Group type: COMPARATOR
Intervention: Granisetron 3.0 mg
Number of subjects: 194
Study 9892475 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg/kg s.c. rHuIL-10
Number of subjects: 17
Study 9892475 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg/kg i.v. rHuIL-10
Number of subjects: 17
Study 8589298 — intervention group
Group type: EXPERIMENTAL
Intervention: CT 110 membrane
Number of subjects: 6
Study 8589298 — intervention group
Group type: EXPERIMENTAL
Intervention: CT 190 membrane
Number of subjects: 6
Study 1976664 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine, 20 mg/day for 4 days
Number of subjects: 10
Study 1976664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 416195 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral total parenteral nutrition (TPN) consisting of casein hydrosylate, dextrose, and soybean emulsion
Number of subjects: 40
Study 416195 — intervention group
Group type: COMPARATOR
Intervention: Nutrition with dextrose and electrolytes (Control)
Number of subjects: 40
Study 31558398 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous thiamine (600 mg on the day of surgery, and 400 mg/day on postoperative days 1, 2, and 3)
Number of subjects: 40
Study 31558398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30412606 — intervention group
Group type: EXPERIMENTAL
Intervention: PEIC (2 x 5)
Number of subjects: 28
Study 30412606 — intervention group
Group type: EXPERIMENTAL
Intervention: PEIC (5 x 2)
Number of subjects: 28
Study 30412606 — intervention group
Group type: COMPARATOR
Intervention: SHAM (2 x 5)
Number of subjects: 28
Study 30412606 — intervention group
Group type: COMPARATOR
Intervention: SHAM (5 x 2)
Number of subjects: 28
Study 25648738 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 μg/day B12 supplementation
Number of subjects: 68
Study 25648738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 24365043 — intervention group
Group type: COMPARATOR
Intervention: parnaparin 8500 UI aXa od for ten days followed by placebo for 20 days
Number of subjects: 664
Study 24365043 — intervention group
Group type: EXPERIMENTAL
Intervention: parnaparin 8500 UI aXa od for ten days followed by 6400 UI aXa od for 20 days
Number of subjects: 664
Study 24365043 — intervention group
Group type: EXPERIMENTAL
Intervention: parnaparin 4250 UI aXa od for 30 days
Number of subjects: 664
Study 22584353 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ganciclovir (1 g t.i.d.)
Number of subjects: 141
Study 22584353 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir (2 g q.i.d.)
Number of subjects: 141
Study 22584353 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive therapy with valganciclovir (900 mg b.i.d. for a minimum of 14 days)
Number of subjects: 141
Study 22584353 — intervention group
Group type: COMPARATOR
Intervention: Deferred therapy
Number of subjects: 141
Study 19800056 — intervention group
Group type: EXPERIMENTAL
Intervention: Rational feeding actions
Number of subjects: 0
Study 19800056 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-rational feeding actions
Number of subjects: 0
Study 18030070 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg tid)
Number of subjects: 61
Study 18030070 — intervention group
Group type: COMPARATOR
Intervention: Usual drug therapy
Number of subjects: 61
Study 16202045 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable partial dentures including molar replacement (RPD_group)
Number of subjects: 34
Study 16202045 — intervention group
Group type: EXPERIMENTAL
Intervention: Retain a premolar occlusion (PROC_group)
Number of subjects: 34
Study 12133061 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy
Number of subjects: 196
Study 12133061 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiotherapy
Number of subjects: 196
Study 12133061 — intervention group
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Number of subjects: 196
Study 12133061 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 196
Study 10484858 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous morphine
Number of subjects: 23
Study 10484858 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous fentanyl
Number of subjects: 23
Study 10484858 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 23
Study 7473034 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in job role quality
Number of subjects: 210
Study 7473034 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in marital role quality
Number of subjects: 210
Study 7473034 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in marital experience (for women)
Number of subjects: 210
Study 1710631 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine hydrochloride (10 and 100 mg/ml)
Number of subjects: 82
Study 1710631 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine phosphate (9%)
Number of subjects: 82
Study 1710631 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance P (50 and 500 ng per injection site)
Number of subjects: 82
Study 1710631 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine (20 micrograms per injection site)
Number of subjects: 82
Study 1710631 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbachol (1 microgram per injection site)
Number of subjects: 82
Study 1710631 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine, codeine phosphate, and substance P
Number of subjects: 82
Study 1710631 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopic examination of skin mast cells
Number of subjects: 82
Study 6754512 — intervention group
Group type: EXPERIMENTAL
Intervention: Org OD 14
Number of subjects: 82
Study 6754512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 31609865 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 12.5 mg naltrexone oral dose (SI group)
Number of subjects: 124
Study 31609865 — intervention group
Group type: COMPARATOR
Intervention: Escalating dosage regimen starting from 50 μg up to a cumulative dose of 12.5 mg (ED group)
Number of subjects: 124
Study 31046713 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and wellbeing financial incentives offered to SMEs
Number of subjects: 0
Study 31046713 — intervention group
Group type: COMPARATOR
Intervention: No monetary incentives (control group)
Number of subjects: 0
Study 28444488 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic swallowing exercises, completed twice daily
Number of subjects: 60
Study 28444488 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60
Study 26837474 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib (75 mg twice daily) plus Docetaxel (75 mg/m2, intravenously on day 1 of every 21-day cycle)
Number of subjects: 634
Study 26837474 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Docetaxel (75 mg/m2, intravenously on day 1 of every 21-day cycle)
Number of subjects: 634
Study 24638003 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib (1 year of adjuvant therapy)
Number of subjects: 645
Study 24638003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 645
Study 24638003 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant imatinib
Number of subjects: 645
Study 22431864 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 60
Study 22431864 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg plus fenofibrate 200 mg
Number of subjects: 60
Study 22431864 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg plus omega-3 fatty acids 2 g
Number of subjects: 60
Study 20707696 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination peer-educator and manager-training intervention
Number of subjects: 110
Study 20707696 — intervention group
Group type: EXPERIMENTAL
Intervention: All three interventions
Number of subjects: 110
Study 20707696 — intervention group
Group type: COMPARATOR
Intervention: Control community (usual care)
Number of subjects: 110
Study 17952029 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid Bonfils endoscope (RBI group, n=59)
Number of subjects: 116
Study 17952029 — intervention group
Group type: COMPARATOR
Intervention: Flexible fiberscope (FFI group, n=57)
Number of subjects: 116
Study 17952029 — intervention group
Group type: COMPARATOR
Intervention: Flexible fiberscope (FFI group)
Number of subjects: 116
Study 17952029 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid Bonfils endoscope (RBI group)
Number of subjects: 116
Study 16277693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine supplementation (50 mg daily for 30 days)
Number of subjects: 0
Study 12126938 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone (800 mg, t.i.d.)
Number of subjects: 21
Study 12126938 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 21
Study 12126938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 10583306 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-6 after dexamethasone
Number of subjects: 16
Study 10583306 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRH after dexamethasone
Number of subjects: 16
Study 10583306 — intervention group
Group type: EXPERIMENTAL
Intervention: GHRP-6 plus GHRH after dexamethasone
Number of subjects: 16
Study 10583306 — intervention group
Group type: COMPARATOR
Intervention: GHRP-6 after placebo
Number of subjects: 16
Study 10583306 — intervention group
Group type: COMPARATOR
Intervention: GHRH after placebo
Number of subjects: 16
Study 10583306 — intervention group
Group type: COMPARATOR
Intervention: GHRP-6 plus GHRH after placebo
Number of subjects: 16
Study 7784126 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 vaccine adjuvanted with alum
Number of subjects: 0
Study 7784126 — intervention group
Group type: COMPARATOR
Intervention: Colombian produced SPf66
Number of subjects: 0
Study 1316066 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin 400 mg oral dose
Number of subjects: 6
Study 1316066 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin up to 800 mg and multiple doses up to 600 mg twice daily (1,200 mg/day)
Number of subjects: 6
Study 1316066 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomefloxacin (all dosage regimens)
Number of subjects: 6
Study 2867573 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone t.i.d.
Number of subjects: 12
Study 2867573 — intervention group
Group type: COMPARATOR
Intervention: Flurazepam
Number of subjects: 12
Study 2867573 — intervention group
Group type: COMPARATOR
Intervention: Triazolam
Number of subjects: 12
Study 2867573 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 12
Study 30927036 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX and trastuzumab
Number of subjects: 45
Study 29396020 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity shockwave therapy sessions once per week for 6 weeks (group A)
Number of subjects: 42
Study 29396020 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity shockwave therapy sessions twice per week for 6 weeks (group B)
Number of subjects: 42
Study 29396020 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat treatment after 6 months (group A received 2 sessions per week, group B received 1 session per week)
Number of subjects: 42
Study 29396020 — intervention group
Group type: EXPERIMENTAL
Intervention: Total number of sessions (6, 12, and 18 sessions)
Number of subjects: 42
Study 26465919 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (100 mg twice daily)
Number of subjects: 46
Study 26465919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 25791068 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung age concept used in smoking cessation counseling
Number of subjects: 29
Study 25791068 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung age concept
Number of subjects: 29
Study 23980091 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg per day for 2 years
Number of subjects: 503
Study 23980091 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 years
Number of subjects: 503
Study 23980091 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib for patients with EGFR wild-type tumors
Number of subjects: 503
Study 23980091 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib for patients with EGFR mutation-positive tumors
Number of subjects: 503
Study 21534899 — intervention group
Group type: EXPERIMENTAL
Intervention: Process redesign to streamline clinical pathways for elective surgery in a dedicated elective surgery facility.
Number of subjects: 0
Study 21534899 — intervention group
Group type: EXPERIMENTAL
Intervention: Dedicated elective surgery facility
Number of subjects: 0
Study 21534899 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical process redesign
Number of subjects: 0
Study 18339031 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (PC(20) = 10.79 mg/L, PC(35) = 8.55 mg/L)
Number of subjects: 22
Study 18339031 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (PC(20) = 237.68 mg/L, PC(35) = 88.72 mg/L)
Number of subjects: 22
Study 16568461 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Cognitive Behavioral Intervention (B‐CBT)
Number of subjects: 90
Study 16568461 — intervention group
Group type: COMPARATOR
Intervention: Assessment Condition (AC)
Number of subjects: 90
Study 16568461 — intervention group
Group type: COMPARATOR
Intervention: Supportive Counseling (SC)
Number of subjects: 90
Study 12674152 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic misuse in the community
Number of subjects: 0
Study 12674152 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors affecting patient compliance to therapy
Number of subjects: 0
Study 10886473 — intervention group
Group type: EXPERIMENTAL
Intervention: Pap test performed as part of pelvic examination in the intervention group
Number of subjects: 111
Study 10886473 — intervention group
Group type: COMPARATOR
Intervention: Usual care group encouraged to schedule a Pap test later
Number of subjects: 111
Study 10886473 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up for abnormal Pap smears in the intervention group
Number of subjects: 111
Study 10886473 — intervention group
Group type: COMPARATOR
Intervention: Follow-up for abnormal Pap smears in the gynecology clinic
Number of subjects: 111
Study 10886473 — intervention group
Group type: EXPERIMENTAL
Intervention: Abnormality rate of Pap smears in urgent care clinic
Number of subjects: 111
Study 10886473 — intervention group
Group type: COMPARATOR
Intervention: Abnormality rate of Pap smears in gynecology clinic
Number of subjects: 111
Study 10886473 — intervention group
Group type: EXPERIMENTAL
Intervention: Specimen adequacy of Pap smears in urgent care clinic
Number of subjects: 111
Study 10886473 — intervention group
Group type: COMPARATOR
Intervention: Specimen adequacy of Pap smears in gynecology clinic
Number of subjects: 111
Study 9386685 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intraaortic balloon pump (IABP) treatment
Number of subjects: 48
Study 9386685 — intervention group
Group type: COMPARATOR
Intervention: Control group (no preoperative IABP)
Number of subjects: 48
Study 7957346 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone intervention (10 mg in 24 h)
Number of subjects: 77
Study 7957346 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of 20 mCi (740 MBq) of technetium‐99m methylene diphosphonate (99mTc‐MDP)
Number of subjects: 77
Study 3591298 — intervention group
Group type: COMPARATOR
Intervention: F1 (1.9 g of protein and 72 kcal per 100 ml)
Number of subjects: 30
Study 3591298 — intervention group
Group type: COMPARATOR
Intervention: F2 (2.7 g of protein and 69 kcal per 100 ml)
Number of subjects: 30
Study 3591298 — intervention group
Group type: EXPERIMENTAL
Intervention: HM (0.96 g of protein and 65 kcal per 100 ml)
Number of subjects: 30
Study 31219152 — intervention group
Group type: EXPERIMENTAL
Intervention: STARTS intervention (Strategies to Avoid Returning to Smoking)
Number of subjects: 300
Study 31219152 — intervention group
Group type: COMPARATOR
Intervention: SUPPORT intervention (attention-controlled comparison)
Number of subjects: 300
Study 29687303 — intervention group
Group type: EXPERIMENTAL
Intervention: Guava leaf extract (1 g daily)
Number of subjects: 0
Study 29687303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29687303 — intervention group
Group type: EXPERIMENTAL
Intervention: Guava leaf extract
Number of subjects: 0
Study 27839596 — intervention group
Group type: EXPERIMENTAL
Intervention: Blurred lens with target laser on
Number of subjects: 11